Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse.

Authors :: Sockel K
Wermke M
Radke J
Kiani A
Schaich M
Bornhäuser M
Ehninger G
Thiede C
Platzbecker U
Source :: Haematologica [Haematologica] 2011 Oct; Vol. 96 (10), pp. 1568-70. Date of Electronic Publication: 2011 Jul 12.
Publication Year :: 2011

Subjects :: Humans
Neoplasm, Residual
Nucleophosmin
Recurrence
Treatment Outcome
Antimetabolites, Antineoplastic therapeutic use
Azacitidine therapeutic use
Leukemia, Myeloid, Acute drug therapy
Leukemia, Myeloid, Acute genetics
Mutation
Nuclear Proteins genetics

Full Text Access

Tools